Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sea Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.74 (market cap $29.60B), while Sea Limited trades at $128.32 (market cap $80.55B). The key difference: Sea Limited is far larger — about 2.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Sea Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SE | |
|---|---|---|
Market Cap | $29.60B | $80.55B |
Sector | Health | Media |
52-Week High | $491.22 | $196.50 |
52-Week Low | $205.48 | $78.16 |
Enterprise Value | $27.56B | $75.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Sea Limited (SE) stock surged 12.11% to $128.7, driven by strong Q2 2026 results with revenue of $7.8 billion, up 48% year-over-year. The company demonstrated robust growth across e-commerce, fintech, and gaming segments, with net income rising 11% to $458 million. Technical indicators show a bullish trend, though RSI levels suggest overbought conditions. Analyst consensus remains positive with a $128.33 price target, supported by improved EBITDA guidance for Shopee.
The outlook for SE is favorable due to accelerating revenue growth and diversification, but risks include margin pressure from increased investments and credit costs. The stock's high P/E ratio of 50.78 demands sustained earnings expansion. Insider selling by the COO warrants monitoring. Overall, growth prospects outweigh near-term challenges, positioning SE for potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
